Pulmonary drug delivery systems: Recent developments and prospects

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 19, Issue 4-5, 2002, Pages 425-498

  Courrier, H M ^a   Butz, N ^a   Vandamme, Th F ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUT CHARLES SADRON   (France)

Author keywords

Carrier; Hydrofluoroalkane; Lung; Pulmonary drug targeting; Specific drug delivery

Indexed keywords

'NANOCRYSTAL'; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ARTIFICIAL LUNG SURFACTANT; BECLOMETASONE DIPROPIONATE; BETA CYCLODEXTRIN DERIVATIVE; BOVINE SERUM ALBUMIN; BUDESONIDE; CONCANAVALIN A; CORTICOSTEROID; CYCLODEXTRIN DERIVATIVE; CYCLOSPORIN A; DEXAMETHASONE; DRUG CARRIER; ERYTHROPOIETIN; GAMMA INTERFERON; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 12; LIPOSOME; MICROSPHERE; NANOPARTICLE; NEDOCROMIL; PACLITAXEL; PEPTIDE; PERFLUOROOCTYL BROMIDE; PIRBUTEROL ACETATE; PROLAIR; PULMOSPHERES; ROLIPRAM; RUBITECAN; SALBUTAMOL; SALCATONIN; SOLKANE; TERBUTALINE; TESTOSTERONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AQUEOUS SOLUTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG TARGETING; GENE THERAPY; HUMAN; LUNG; LUNG ALVEOLUS MACROPHAGE; LUNG DIFFUSION; LUNG DISEASE; MELANOMA; METASTASIS; METERED DOSE INHALER; MICELLE; MICROEMULSION; MUCOCILIARY CLEARANCE; NONHUMAN; PARTICLE SIZE; POWDER INHALER; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY SYSTEM; REVIEW; SUSTAINED DRUG RELEASE;

ADMINISTRATION, INHALATION; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; EMULSIONS; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; PHARMACEUTICAL SOLUTIONS; SUSPENSIONS;

EID: 0036940766     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v19.i45.40     Document Type: Review

References (172)

1. Zheng Y, Marsh KC, Bertz RJ, El-Shourbagy T, Adjei AL. Pulmonary delivery of a dopamine D-1 agonist, ABT-431, in dogs and humans. Int J Pharm 1999; 191:131-140.
2. Thompson PJ. Drug delivery to the small airways. Am J Respir Crit Care Med 1998; 157: S199-S202.
3. Ariyananda PL, Agnew JE, Clarke SW. Aerosol delivery systems for bronchial asthma. Postgrad Med J 1996; 72:151-156.
4. Brooks AD, Tong W, Benedetti F, Kaneda Y, Miller V, Warrell RP. Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. Cancer Chemother Pharm 2000; 46:313-318.
5. Gonda I. The ascent of pulmonary drug delivery. J Pharm Sci 2000; 89:940-945.
6. Newhouse MT. Tennis anyone? The lungs as a new court for systemic therapy. CMAJ 1999; 161:1287-1288.
7. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim Biophys Acta 1998; 1408:79-89.
8. Johansson J, Curstedt T, Robertson B. The proteins of the surfactant system. Eur Respir J 1994; 7:372-391.
9. Morley CJ. Surfactant treatment for premature babies - a review of clinical trials. Arch Dis Child 1991; 66:445-450.
10. Nicholas TE. Pulmonary surfactant: no mere paint on the alveolar wall. Respirology 1996; 1:247-257.
11. Suresh GK, Soll R.F. Current surfactant use in premature infants. Clin Perinatol 2001; 28:671-694.
12. Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER. Cell number and cell characteristics of normal human lung. Am Rev Respir Dis 1982; 126:332-337.
13. Weibel ER. Morphometry of the human lung: the state of the art after two decades. Bull Eur Physiopathol Respir 1979; 15:999-1013.
14. Fuchs NA, Sutugin P. The mechanies of aerosols. In: Davies CN, editor. Aerosol Science. London: University Press, 1966.
15. Washington N, Washington C, Wilson CG. Pulmonary drug delivery. In: Washington N, Washington C, Wilson CG, editors. Physiological Pharmaceutics: Barriers to Drug Absorption New York: Taylor and Francis, 2000.
16. Gonda I. A semi-empirical model of aerosol deposition in the human respiratory tract for mouth inhalation. J Pharm Pharmacol 1981; 33:692-696.
17. Philipson K, Falk R, Svartengren M, Jarvis N, Bailey M, Bergmann R, Hofmann W, Camner P. Does lung retention of inhaled particles depend on their geometric diameter? Exp Lung Res 2000; 26:437-455.
18. Patton J.S. Mechanisms of macromolecule absorption by the lungs. Adv Drug Del Rev 1996; 19:3-36.
19. Houtmeyers E, Gosselink R, Gayan-Ramirez G, Decramer M. Regulation of mucociliary clearance in health and disease. Eur Respir J 1999; 13:1177-1188.
20. Jones JG. Clearance of inhaled particles from the alveoli. In: Clarke SW, editor. Aerosol and the Lung: Clinical and Experimental Aspects. London: Butterworth, 1984.
21. Evora C, Soriano I, Rogers RA, Shakesheff KM, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release 1998; 51:143-152.
22. Ng K, Stringer KA, Cohen Z, Serravo R, Tian B, Meyer JD, Falk R, Randolph T, Manning MC, Thompson DC. Alveolar macrophage cell line is not activated by exposure to polymeric microspheres. Int J Pharm 1998; 170:41-49.
23. Mihalko PJ, Schreier H, Abra RM. Liposomes: a pulmonary perspective. In: Gregoriadis G., editor. Liposomes as Drug Carriers. Wiley, 1988.
24. Beaulac C, Clement-Major S, Hawari J, Lagace J. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J Microencapsul 1997; 14:-348.
25. Joshi M, Misra A. Dry powder inhalation of liposomal Ketotifen fumarate: formulation and characterization. Int J Pharm 2001; 223:15-27.
26. Kellaway IW, Farr S. Liposomes as drug delivery systems to the lungs. Adv Drug Del Rev 1990; 5:149-161.
27. Zeng XM, Martin GP, Marriott C. The controlled delivery of drugs to the lung. Int J Pharm 1995; 124:149-164.
28. Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 1996; 9:111-122.
29. Myers MA, Thomas DA, Straub L, Soucy DW, Niven RW, Kaltenbach M, Hood CI, Schreier H, Gonzales-Rothi RJ. Pulmonary Effects of chronic exposure to liposome aerosol in mice. Exp Lung Res 1993; 19:1-19.
30. Forsgren P, Modig J, Gerdin B, Axelsson B, Dahlback M. Intrapulmonary deposition of acrosolized Evans blue dye and liposomes in an experimental porcine model of early ARDS. Ups J Med Sci 1990; 95:117-136.
31. Gilbert BE, Wilson SZ, Garcon NM, Wyde PR, Knight V. Characterization and administration of cyclosporine liposomes as a small-particle aerosol. Transplantation 1993; 56:974-977.
32. Waldrep JC, Keyhani K, Black M, Knight V. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994; 105:106-110.
33. Waldrep JC, Arppe J, Jansa KA, Knight V. High dose cyclosporin A and budesonide-liposome aerosols. Int J Pharm 1997; 152:27-36.
34. Waldrep JC, Arppe J, Jansa KA, Vidgren M. Experimental pulmonary delivery of cyclosporin A by liposome aerosol. Int J Pharm 1998; 160:239-249.
35. Arppe J, Vidgren M, Waldrep JC. Pulmonary pharmacokinetics of cyclosporin A liposomes. Int J Pharm 1998; 161:205-214.
36. Letsou GV, Safi HJ, Reardon MJ, Ergenoglu M, Li Z, Klonaris CN, Baldwin JC, Gilbert BE, Waldrep JC. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann Thorac Surg 1999; 68:2044-2048.
37. Gonzales-Rothi RJ, Suarez S, Hochhaus G, Schreier H, Luckyanov A, Derendorf H, Dalla Costa T. Pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 1996; 13:1699-1703.
38. Benameur H, Latour N, Schandene L, Van Vooren JP, Flamion B, Legros FJ. Liposome-incorporated dexamethasone palmitate inhibits in-vitro lymphocyte response to mitogen. J Pharm Pharmacol 1995; 47:812-817.
39. Suntres ZE, Shek PN. Liposomes promote pulmonary glucocorticoid delivery. J Drug Target 1998; 6:175-182.
40. Suntres ZE, Shek PN. Prophylaxis against lipopolysaccharide-induced lung injuries by liposome-entrapped dexomethasone in rats. Biochem Pharmacol 2000; 59:1155-1161.
41. Saari M,Vidgren MT, Koskinen MO, Turjanmaa VMH, Nieminen MM. Pulmonary distribution and clearance of two beclomethasone liposome formulations in healthy volunteers. Int J Pharm 1999; 181:1-9.
42. Darwis Y, Kellaway IW. Nebulisation of rehydrated freeze-dried beclomethasone dipropionate liposomes. Int J Pharm 2001; 215:113-121.
43. Demaeyer P, Akodad EM, Gravet E, Schietecat P, Van Vooren JP, Drowart A, Yernault JC, Legros FJ. Disposition of liposomal gentamicin following intrabronchial administration in rabbits. J Microencapsul 1993; 10:77-88.
44. Hung OR, Whynot SC, Varvel JR, Shafer SL, Mezei M. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anesthesiology 1995; 83:277-284.
45. Suntres ZE, Hepworth SR, Shek PN. Pulmonary uptake of liposome-associated alpha-tocopherol following intratracheal instillation in rats. J Pharm Pharmacol 1993; 45:514-520.
46. Suntres ZE, Shek PN. Liposomal α-tocopherol alleviates the progression of paraquat-induced lung damage. J Drug Target 1995; 2:493-500.
47. Lange CF, Hancock RE, Samuel J, Finlay WH. In vitro aerosol delivery and regional airway surface liquid concentration of liposomal cationic peptide. J Pharm Sci 2001; 901647-1657.
48. Goldbach P, Dumont S, Kessler R, Poindron P, Stamm A. Preparation and characterization of interferon-containing liposomes. Int J Pharm 1995; 123:33-39.
49. Kanaoka E, Nagata S, Hirano K. Stabilization of aerosolized IFN-gamma by liposomes. Int J Pharm 1999; 188:165-172.
50. Saravolac EG, Sabuda D, Crist C, Blasetti K, Schnell G, Yang H, Kende M, Levy HB, Wong JP. Immunoprophylactic strategies against respiratory influenza virus infection. Vaccine 2001; 19:2227-2232.
51. Khanna C, Hasz DE, Klausner JS, Anderson PM. Aerosol delivery of interleukin 2-liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res 1996; 2:721-734.
52. Ten RM, Anderson PM, Zein NN, Temesgen Z, Clawson ML, Weiss W. Interleukin-2 liposomes for primary immune deficiency using the aerosol route. Int Immunopharmacol 2002; 2:333-344.
53. Liu FY, Shao Z, Kildsig DO, Mitra AK. Pulmonary delivery of free and liposomal insulin. Pharm Res 1993;10:228-232.
54. Mitra R, Pezron I, Li Y, Mitra AK. Enhanced pulmonary delivery of insulin by lung lavage fluid and phospholipids. Int J Pharm 2001; 217:25-31.
55. Canonico AE, Plitman JD, Conary JT, Meyrick BO, Brigham KL. No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes. J Appl Physiol 1994; 77:415-419.
56. Schwarz LA, Johnson JL, Black M, Cheng SH, Hogan ME, Waldrep JC. Delivery of DNA-cationic liposome complexes by small-particle aerosol. Hum Gene Ther 1996; 7:731-741.
57. McDonald RJ, Liggitt HD, Roche L, Nguyen HT, Pearlman R, Raabe OG, Bussey LB, Gorman CM. Aerosol delivery of lipid:DNA complexes to lungs of rhesus monkeys. Pharm Res 1998; 15:671-679.
58. Desmore CL, Giddings TH, Waldrep JC, Kinsey BM, Knight V. Gene transfer by guadinium-cholesterol: dioleoylphosphatidyl-ethanolamine liposome-DNA complexes in aerosol. J Gene Med 1999; 1:251-264.
59. Knight V, Koshkina N, Waldrep JC, Giovanella BC, Kleinerman E, Gilbert B. Anti-cancer activity of 9-nitrocamptothecin liposome aerosol in mice. Trans Am Clin Climatol Assoc 2000; 111:135-145.
60. Koshkina NV, Kleinerman ES, Waldrep JC., Jia SF, Worth LL, Gilbert BE, Knight V. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin Cancer Res 2000; 6:2876-2880.
61. Koshkina NV, Knight V, Gilbert BE, Golunski E, Roberts L, Waldrep JC. Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies. Cancer Chemoth Pharm 2001; 47:451-456.
62. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight VP. Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 2001; 7:3258-3262.
63. Lehr C-M. Lectin-mediated drug delivery: the second generation of bioadhesives. J Control Release 2000; 65:19-29.
64. Abu-Dahab R, Schäfer UF, Lehr C-M. Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. Eur J Pharm Sci 2001; 14:37-46.
65. Margalit R. Liposome-mediated drug targeting in topical and regional therapies. Crit Rev Ther Drug Carrier Syst 1995; 12:233-261.
66. Steiner SS, Feldstein R, Lian H, Rhodes C, Shen G. Method for drug delivery to the pulmonary system. WO 96/36314, 1996.
67. El-Baseir MM, Kellaway IW. Poly(-lactic acid) microspheres for pulmonary drug delivery: release kinetics and aerosolization studies. Int J Pharm 1998; 175:135-145.
68. Sakagami M, Sakon K, Kinoshita W, Makino Y. Enhanced pulmonary absorption following aerosol administration of mucoadhesive powder microspheres. J Control Release 2001; 77:117-129.
69. Zeng XM, Martin GP, Marriott C. Preparation and in vitro evaluation of tetrandrine-entrapped albumin microspheres as an inhaled drug delivery system. Eur J Pharm Sci 1995; 3:87-93.
70. Li FQ, Hu JH, Lu B, Yao H, Zhang WG. Ciprofloxacin-loaded bovine serum albumin microspheres: preparation and drug-release in vitro. J Microencapsul 2001; 18:825-829.
71. Wang D, Robinson DR, Kwon GS, Samuel J. Encapsulation of plasmid DNA in biodegradable poly(D,L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J Control Release 1999; 57:9-18.
72. Wichert B, Rohdewald P. Low molecular weight PLA: a suitable polymer for pulmonary administered microparticles? J Microencapsul 1993; 10:195-207.
73. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, McMurray DN, Hickey AJ. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001; 18:1315-1319.
74. Morimoto K, Katsumata H, Yabuta T, Iwanaga K, Kakemi M, Tabata Y, Ikada Y. Gelatin microspheres as a pulmonary delivery system: evaluation of salmon calcitonin absorption. J Pharm Pharmacol 2000; 52:611-617.
75. Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst 1996; 13:1385-184.
76. Bittner B, Morlock M, Koll H, Winter G, Kissel T. Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics. Eur J Pharm Biopharm 1998; 45:295-305.
77. Blanco D, Alonso MJ. Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants. Eur J Pharm Biopharm 1998; 45:285-294.
78. Greenway TE, Eldridge JH, Ludwig G, Staas JK, Smith JF, Smith JF, Gilley RM, Michalek SM. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine. Vaccine 1998; 16:1314-1323.
79. Eyles JE, Williamson ED, Spiers ID, Alpar HO. Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine 2000; 18:3266-3271.
80. Rogerson CV, Osborne NB. Microparticles and their therapeutic or diagnostic use. WO 99/32083, 1999.
81. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science 1997; 276:1868-1871.
82. Weers JG, Dellamary LA. Stabilized preparations for use in metered dose inhalers. WO 99/ 16422, 1999.
83. Speiser PP. Poorly soluble drugs, a challenge in drug delivery. In: Müller RH, Benita S, Böhm B, editors. Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs. Stuttgart: Med. Pharm. Scientific Publishers; 1998.
84. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Properties of a peptide containing DL lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur J Pharm Biopharm 1998; 45:41-48.
85. Mc Intire GL, Bacon ER, Toner JL, Cornacoff JB, Losco PE, Illig KJ, Nikula KJ, Muggenburg BA, Ketai L. Pulmonary delivery of nanoparticles of insoluble, iodinated CT X-ray contrast agents to draining lymph nodes in dogs. J Pharm Sci 1998; 87:1466-1470.
86. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70:1-20.
87. Dunn JM. Drug delivery systems for macromolecular drugs. WO 97/04747, 1997.
88. Takeuchi H, Yamamoto H, Kawashima Y. Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Del Rev 2001; 47:39-54.
89. Kawashima Y, Yamamoto H, Takeuchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release 1999; 62:279-287.
90. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats. Int J Pharm 2001; 218:75-80.
91. Feng SS, Mu L, Chen BH, Pack D. Polymeric nanospheres fabricated with natural emulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol®). Mat Sci Eng C 2002; 20:85-92.
92. Armstrong DJ, Elliott PNC, Ford JL, Gadson D, McCarthy GP, Rostron C, Worsley MD. Poly-(D, L-lactic acid) microspheres incorporating histological dyes for intra-pulmonary histopathological investigations. J Pharm Pharmacol 1996; 48:258-262.
93. Müller RH, Maassen S, Weyhers H, Specht F, Lucks JS. Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int J Pharm 1996; 138:85-94.
94. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - review of the state of the art. Eur J Pharm Biopharm 2000; 50:161-177.
95. Loftsson T, Brewster ME. Cyclodextrins as pharmaceutical excipients. Pharm Technol Eur 1997; 9:26-34.
96. Dûchene D, editor. Cyclodextrins and their industrial uses. Paris: Editions de Santé, 1987.
97. Dûchene D, Wouessidjewe D, Ponchel G. Cyclodextrins and carrier systems. J Control Release 1999; 62:263-268.
98. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 1997; 86:147-162.
99. Cabral Marques HM, Hadgraft J. Studies of cyclodextrin inclusion complexes: the pulmonary absorption of β-, DM-β- and HP-β-cyclodextrin in rabbits. Int J Pharm 19991; 77:297-302.
100. Chetty DJ, Chien YW. Novel methods of insulin delivery: an update. Crit Rev Ther Drug Carrier Syst 1998; 15:629-670.
101. Kobayashi S, Kondo S, Juni K. Pulmonary delivery of salmon calcitonin dry powders containing absorption enhancers in rats. Pharm Res 1996; 13:80-83.
102. Bennett DB, Tyson E, Nerenberg CA, Mah S, de Groot JS, Teitelbaum Z. Pulmonary delivery of detirelix by intratracheal instillation and aerosol inhalation in the briefly anesthetized dog. Pharm Res 1994; 11:1048-1055.
103. Bray M, Martinez M, Kefauver D, West M, Roy C. Treatment of aerosolized cowpox virus infection in mice with aerosolized cidofovir. Antiviral Res 2002; 54:129-142.
104. Ward ME, Woodhouse A, Mather LE, Farr S, Okikawa JK, Lloyd P, Schuster JA, Rubsamen RM. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmacol Ther 1997; 62:596-609.
105. Farr SJ, McElduff A, Mather LE, Okikawa J, Ward ME, Gonda I, Licko V, Rubsamen RM. Pulmonary insulin administration using the AERx system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Therapeut 2000; 2:185-197.
106. Moya FR, Llanos AJ, Rios AM, Riquelme RA, Moraga FA, Rubio LA, Salvo HD, Jacobs HC. Repeated doses of the perfluocarbon FC-100 improve lung function of preterms lambs. Pediatr Res 1997; 42:893-897.
107. Desmore CL, Orson FM, Xu B, Kinsey BM, Waldrep JC, Hua P, Bhogal B, Knight V. Aerosol delivery of robust polyethylenimine-DNA complexes for gene therapy and genetic immunization. Mol Ther 2000; 1:180-188.
108. Gautam A, Densmore CL, Xu B, Waldrep JC. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol Ther 2000; 2:63-70.
109. Gautam A, Densmore CL, Waldrep JC. Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy. Gene Ther 2001; 8:254-257.
110. Desmore CL, Kleinerman ES, Gautam A, Jia SF, Xu B, Worth LL, Waldrep JC, Fung YK, T'Ang A, Knight V. Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther 2001; 8619-627.
111. Ostrander KD, Bosch HW, Bondanza DM. An in-vitro assessment of a NanoCrystal™ beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur J Pharm Biopharm 1999; 48:207-215.
112. Shaffer TH, Wolfson MR, Greenspan JS. Liquid ventilation: current status. Pediatr Rev 1999; 20:134-142.
113. Gauger PG, Overbeck MC, Chambers SD, Cailipan CI, Hirschl RB. Partial liquid ventilation improves gas exchange and increases EELV in acute lung injury. J Appl Physiol 1998; 84:1566-1572.
114. Greenspan JS, Wolfson MR, Shaffer TH. Liquid ventilation: clinical experiences. Biomed Instrument Technol 1999; 33:253-259.
115. Steinhorn DM, Papo MC, Rotta AT, Aljada A, Fuhrman BP, Dandona P. Liquid ventilation attenuates pulmonary oxidative damage. J Crit Care 1999; 14:20-28.
116. Wolfson MR, Greenspan JS, Shaffer TH. Pulmonary administration of vasoactive substances by perfluorochemical ventilation. Pediatrics 1996; 97:449-455.
117. Kimless-Garber DB, Wolfson MR, Carlsson C, Shaffer TH. Halothane administration during liquid ventilation. Resp Med 1997; 91:255-262.
118. Scherer PW, Haselton FR. Convective exchange in oscillatory flow through bronchial-tree models. J Appl Physiol 1982; 53:1023-1033.
119. Cox CA, Cullen AB, Wolfson MR, Shaffer TH. Intratracheal administration of perfluorochemical-gentamicin suspension: a comparison to intravenous administration in normal and injured lungs. Pediatr Pulm 2001; 32:142-151.
120. Fox WW, Weis CM, Cox C, Farina C, Drott H, Wolfson MR, Shaffer TH. Pulmonary administration of gentamicin during liquid ventilation in a newborn lamb lung injury model. Pediatrics 1997; 100:1-7.
121. Cullen AB, Cox CA, Hipp SJ, Wolfson MR, Shaffer TH. Intra-tracheal delivery strategy of gentamicin with partial liquid ventilation. Respir Med 1999; 93:770-778.
122. Nakazawa K, Yokoyama K, Matsuzawa Y, Makita K, Amaha K. Pulmonary administration of prostacyclin (PGI2) during partial liquid ventilation in an oleic acid-induced lung injury: inhalation of aerosol or intratracheal instillation? Intens Care Med 2001; 27:243-250.
123. Chappell SE, Wolfson MR, Shaffer TH. A comparison of surfactant delivery with conventional mechanical ventilation and partial liquid ventilation in meconium aspiration injury. Resp Med 2001; 95:612-617.
124. Anda GFV, Lachmann B. Treatment and prevention of acute respiratory failure; physiological basis. Arch Med Res 2001; 32:91-101.
125. Haitsma JJ, Lachmann U, Lachmann B. Exogenous surfactant as a drug delivery agent. Adv Drug Del Rev 2001; 47:197-207.
126. Herting E, Gan X, Rauprich P, Jarstrand C, Robertson B. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B streptococcal pneumonia. Am J Respir Crit Care Med 1999; 159:1862-1867.
127. Malcolmson RJ, Embleton JK. Dry powder formulations for pulmonary delivery. PSTT 1998; 1:394-398.
128. LiCalsi C, Christensen T, Bennett JV, Phillips E, Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine 1999; 17:1796-1803.
129. Patton JS. Pulmonary delivery of drugs for bone disorders. Adv Drug Del Rev 2000; 42:239-248.
130. Steckel H, Thies J, Müller BW. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int J Pharm 1997; 152:99-110.
131. Todo H, Okamoto H, Iida K, Danjo K. Effect of additives on insulin absorption from intratracheally administrated dry powders in rats. Int J Pharm 2001; 220:101-110.
132. Bosquillon C, Lombry C, Préat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release 2001; 70:329-339.
133. Taljanski W, Pierzynowski SG, Lundin PD, Westrom BR, Eirefel S, Podlesny J, Dahlback M, Siwinska-Golebiowska H, Karlsson BW. Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats. Drug Metab Dispos 1997; 25:917-920.
134. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Del Rev 2000; 45:89-121.
135. Patel N, Marlow M, Lawrence MJ. Microemulsions: a novel pMDI formulation. In: Patel N, Marlow M, Lawrence MJ, editors. Drug Delivery to the Lungs IX, London: The Aerosol Society, Bristol, 1998.
136. Evans RM. Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations. US Patent 5,230,884; 1993.
137. Sommerville ML, Cain JB, Johnson CS, Hickey AJ. Lecithin inverse microemulsions for the pulmonary delivery of polar compounds utilizing dimethylether and propane as propellants. Pharm Dev Tech 2000; 5:219-230.
138. Sadtler VM, Krafft MP, Riess JG. Achieving stable, reverse water-in-fluorocarbon emulsions. Angew Chem Int Ed Engl 1996; 35:1976-1978.
139. Sadtler VM, Krafft MP, Riess JG. Reverse water-in-fluorocarbon emulsions as drug delivery system: an in vitro study. Colloid Surface A, 1999; 147:309-315.
140. Courrier HM, Rawiso M, Vandamme ThF, Krafft MP. Emulsification behavior of a fluorinated amphiphile at the interface between a fluorocarbon and water. Colloid Surf A 2003 (submitted).
141. Courrier HM, Krafft MP, Butz N, Porté C, Frossard N, Remy-Kristensen A, Mely Y, Pons F, and Vandamme ThF. Evaluation of cytotoxicity of new semi-fluorinated amphiphiles derived from dimorpholinophosphate. Biomaterials 2003; 24:689-696.
142. Aiache J-M. The ideal drug delivery system: a look into the future. J Aerosol Med 1991; 4:323-334.
143. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug 1995; 12:151-231.
144. Kontny MJ, Destefano G, Jager PD, McNamara DP, Turi JS, Van Campen L. Issues surrounding MDI formulation development with non-CFC propellants. J Aerosol Med 1991; 4:181-187.
145. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers - into the new millennium. Int J Pharm 2000; 201:89-107.
146. Chinet T. Changes in metered dose inhaler propellants. Rev Malad Respirat 2000; 17:15-20.
147. Purewal TS. Alternative propellants for metered dose inhalers. Aerosol Spray Rep 1998; 37:20-25.
148. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999; 12: S9-S17.
149. Graepel P, Alexander DJ. CFC replacements: safety testing, approval for use in metered dose inhalers. J Aerosol Med 1991; 4:193-200.
150. Aiache JM. Problèmes posés par la reformulation des inhalations après la suppression des propulseurs "Les chlorofluorocarbones (CFC)". Ann Pharmaceut Franç 1997; 55:62-68.
151. Alexander DJ, Libretto SE. An overview of the toxicology of HFA-134a (1,1,1,2-tetrafluoroethane). Hum Exp Toxicol 1995; 14:715-720.
152. Emmen HH, Hoogendijk EM, Klöpping-Ketelaars WA, Muijser H, Duistermaat E, Ravensberg JC, Alexander DJ, Borkhataria D, Rusch GM, Schmit B. Human safety and pharmacokinetics of the CFC alternative propellants HFC 134a (1,1,1,2-tetrafluoroethane) and HFC 227 (1,1,1,2,3,3,3-heptafluoropropane) following whole-body exposure. Regul Toxicol Pharm 2000; 3222-3235.
153. Harrison LI. Pharmacokinetics of HFA-134a: a preliminary report. Am J Ther 1996; 3:763-765.
154. Williams III RO, Repka M, Liu J. Influence of propellant composition on drug delivery from a pressurized metered-dose inhaler. Drug Dev Ind Pharm 1998; 24:763-770.
155. Leach C.L. Improved delivery of inhaled steroids to the large and small airways. Resp Med 1998; 92:3-8.
156. Keller M. Innovations and perspectives of metered dose inhalers in pulmonary drug delivery. Int J Pharm 1999; 186:81-90.
157. Vanden Burgt JA, Busse WW, Martin RJ, Szefler SJ, Donnell D. Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma. J Allergy Clin Immunol 2000; 106:1210-1226.
158. Cummings RH. Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performance. J Allergy Clin Immunol 1999; 104:S230-S235.
159. Brindley A. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. J Allergy Clin Immunol 1999; 104:S221-S226.
160. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm 1999; 86:13-30.
161. Dickinson PA, Seville PC, McHale H, Perkins NC, Taylor G. An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants. J Aerosol Med 2000; 13:179-186.
162. Williams III RO, Liu J. Formulation of a protein with propellant HFA 134a for aerosol delivery. Eur J Pharm Sci 1999; 7:137-144.
163. Tansey I. The technical transition to CFC-free inhalers. Brit J Clin Pract 1997; 89:22-27.
164. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Resp Med 2000; 94:S3-S9.
165. Smith IJ. The challenge of reformulation. J Aerosol Med 1995; 8:S19-S27.
166. Tiwari D, Goldman D, Dixit S, Malick WA, Madan PL. Compatibility evaluation of metereddose inhaler valve elastomers with tetrafluoroethane (P134a), a non-CFC propellant. Drug Dev Ind Pharm 1998; 24:345-352.
167. Tansey I. The challenges in the development of metered dose inhalation aerosols using ozone-friendly propellants. Spray Technol Market 1994; 4:26-29.
168. Dellamary LA, Tarara TE, Smith DJ, Woelk CH, Adractas A, Costello ML, Gill H, Weers JG. Hollow porous particles in metered dose inhalers. Pharm Res 2000; 17:168-174.
169. Bot AI, Tarara TE, Smith DJ, Bot SR, Woods CM, Weers JG. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 2000; 17:275-283.
170. Williams III RO, Barron MK, Alonso MJ, Remuñán-López C. Investigation of a pMDI system containing chitosan microspheres and P134a. Int J Pharm 1998; 174:209-222.
171. Dickinson PA, Howells SW, Kellaway IW. Novel nanoparticles for pulmonary drug administration. J Drug Target 2001; 9:295-302.
172. Butz N, Porté C, Courrier HM, Krafft MP, Vandamme ThF. Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants. Int J Pharm 2002; 238:257-269.